Compare FSTR & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSTR | AQST |
|---|---|---|
| Founded | 1902 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.8M | 521.0M |
| IPO Year | 1995 | 2007 |
| Metric | FSTR | AQST |
|---|---|---|
| Price | $28.24 | $4.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $32.00 | $9.00 |
| AVG Volume (30 Days) | 18.1K | ★ 1.9M |
| Earning Date | 03-03-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $540,009,000.00 | $67,430,000.00 |
| Revenue This Year | $5.44 | $14.23 |
| Revenue Next Year | $3.05 | $58.36 |
| P/E Ratio | $40.77 | ★ N/A |
| Revenue Growth | ★ 1.74 | 0.77 |
| 52 Week Low | $17.16 | $2.20 |
| 52 Week High | $32.63 | $7.55 |
| Indicator | FSTR | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 39.61 | 47.02 |
| Support Level | $27.78 | $3.69 |
| Resistance Level | $29.72 | $4.46 |
| Average True Range (ATR) | 1.31 | 0.20 |
| MACD | -0.23 | -0.01 |
| Stochastic Oscillator | 22.38 | 25.78 |
L.B. Foster Co is a technology solutions provider of products and services for the rail and infrastructure markets. The company has two reporting segments: Rail, Technologies, and Services (Rail); and Infrastructure Solutions (Infrastructure). Maximum revenue is generated from the Rail segment, which is comprised of several manufacturing and distribution businesses that provide products and services for freight and passenger railroads and industrial companies throughout the world. The Infrastructure segment offers engineered precast concrete solutions, as well as fabricated bridge, protective pipe coating, and pipe threading offerings across North America. Geographically, the company generates maximum revenue from the United States, followed by Canada, the UK, and other markets.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.